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1 Supplemental materials 
 
1.1 Participants 
The following clinical information was available for each subject: age at testing, date of testing, sex, mutation status (presymptomatic mutation 
carrier, PMC; affected mutation carrier, AMC; non-carrier, NC) and years of education. In addition, information on mutated gene (chromosome 
9 open reading frame 72, C9orf72; progranulin, GRN; microtubule associated protein tau, MAPT or TANK-binding kinase 1, TBK1) was available 
for mutation carriers, and diagnosis as well as age at onset for affected mutation carriers (AMC). 
The mean age at onset for mutation carriers has in a recent publication by Moore et al., 2019(1) been estimated to be 58.2 years for C9orf72, 
61.3 years for GRN and 49.5 years for MAPT. Years to expected onset was calculated based on the age of the participant minus the mean age at 
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onset for the specific mutated gene segregating in the family. For example, a 45 years old C9orf72 mutation carrier was estimated to be 13.2 
years from expected symptom onset (45 - 58.2 = -13.2). 
1.2 Neuropsychological tests 
359 participants were assessed using GENFI 1 protocol (2012-2015) and 444 participants using GENFI 2 protocol (2015-2018)(2). The following 
tasks were included in both GENFI 1 and GENFI 2 (i.e. all 803 participants performed the tasks): Block design(3), Boston naming test (BNT)(4), 
Digit symbol(3), Digit span (forward and backward)(3), Trail making test A (TMT A) and B (TMT B)(5) and Verbal fluency test (animals, letters F, A 
and S)(6). In GENFI 2 (n=444), the following additional tests were administered: Benson figure copy, recall and recognition(7), modified Camel 
and cactus test (CC)(8), Stroop colour and word test (ink and word naming, interference)(9,10), Free and cued selective reminding test 
(FCRST)(11), Ekman faces and Faux pas recognition test as part of the mini-SEA(12). All neuropsychological raw scores were converted into z-
scores. z-scores were calculated based on mutation negative control data (individual test score minus the mean of non-carriers, divided by the 
standard deviation of non-carriers) and were corrected for language in language specific tasks (i.e. BNT and Verbal fluency). 
1.3 Composite scores 
Composite scores were calculated from reflecting different cognitive domains: language, executive function, attention and processing speed, 
memory, social cognition and visuoconstruction. The composite scores were calculated as the mean of the z-scores of the individual tests included 
in the composite (13). We treat the composite value as an estimate of a standardised score, meaning that a value of 1 is approximately 1 standard 
deviation (SD). The composite score of language included BNT, CC and Verbal fluency animals; executive function included TMT B, Verbal fluency 
letters, Digit span backward and Stroop interference; attention and processing speed included TMT A, Digit symbol, Digit span forward and Stroop 
ink and word naming; memory included Digit span (forward and backward) and FCRST; social cognition included Ekman faces and Faux pas 
recognition test (mini-SEA); and visuoconstruction included Block design and Benson figure. If there were missing data from a specific task (if a 
participant did not complete the whole test battery), the domain composite score was calculated based on the remaining test scores for that 
domain, i.e. the sum of the z-scores divided by the number of completed tests. As a sensitivity analysis, we excluded the individuals with less 
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than two thirds of completed tests (n=5) and re-ran the mixed effect model of global cognitive score. The results were the same and did not 
change the conclusion. 
1.4 Statistical analysis 
All statistical analyses and visual illustrations were performed using R version 4.0.3. P-values below 0.05 were considered statistically significant 
and baseline p-values were adjusted for multiple comparisons using Bonferroni corrections (number of comparisons = 63). Assumptions were 
assessed visually by residual plots (independence and equal variance) and normal probability plots (normality). 
When assessing mean differences in numeric variables between NC, PMC and AMC, One-way ANOVA with Bonferroni post hoc tests was used 
(age, years of education). Chi-square tests were used for assessing sex distribution in NC, PMC and AMC.  
 
Model selection(14) was based upon clinical relevance and Bayesian information criterion (BIC), where lower BIC was preferred. A stepwise 
backward selection was performed for the fixed effects using R package lmerTest v2.0-36. Mutation group (AMC, PMC or NC) or mutated gene 
(C9orf72, GRN, MAPT, NC), visit, years from baseline visit, age, age^2, education, sex and baseline score were included as fixed effects 
(independent variables) in the final models. In addition, the interaction between gene and visit was included to investigate whether the 
trajectories for neuropsychological test scores were different over time depending on which gene was mutated. Site and individual were included 
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Supplementary Table 1. Demographic data. NC, non-carriers; PMC, presymptomatic mutation carriers; AMC, affected mutation carriers; C9orf72, chromosome 9 open reading frame 72; GRN, 
progranulin; MAPT, microtubule associated protein tau; TBK1, TANK-binding kinase 1; SD, standard deviation. 
 Mutation group  Test statistic  
 NC PMC AMC Total p value  
N 317 327 159 803   
Age (Years)     < 0.001
a AMC > PMC = NC 
  Mean (SD) 46.2 (14.0) 44.4 (12.0) 62.6 (8.0) 48.7 (14.0)   
  Range 19.4 - 85.7 20.1 - 75.5 37.9 - 78.7 19.4 - 85.7   
Sex          0.01
b  
  Females (%) 182 (57.4) 198 (60.6) 65 (40.9) 445 (55.4)   
Education (Years)     < 0.001
c AMC < PMC = NC 
  Mean (SD) 11.0 (3.5) 11.3 (3.3) 9.2 (3.9) 10.8 (3.6)   
  Range 2.0 - 21.0 2.0 - 21.0 1.0 - 19.0 1.0 - 21.0   
Mutated gene (%)       
  C9orf72  121 (37.0) 79 (49.7) 200 (24.9)   
  GRN  148 (45.3) 52 (32.7) 200 (24.9)   
  MAPT  58 (17.7) 27 (17.0) 85 (10.6)   
  TBK1  0 (0.0) 1 (0.6) 1 (0.1)   
a ANOVA. Differences in age between AMC vs PMC and AMC vs NC. No difference between PMC and NC.  
b Pearson's Chi-squared test.  
c ANOVA. Difference in years of education between AMC vs PMC and AMC vs NC. No difference between PMC and NC. 
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Supplementary Figure 1. Bar chart illustrating the number of participants at each visit. NC, non-carriers; PMC, presymptomatic mutation carriers; AMC, affected mutation carriers. 
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Supplementary Figure 2. Trajectories of global cognitive test scores, fitted line from mixed effect model. The model included mutation group (AMC, PMC, NC), visit (1-5), mutation group:visit, 
years from baseline visit, age, age^2, education, sex and baseline score as fixed effects and site and individual as random effects. NC, non-carriers; PMC, presymptomatic mutation carriers; 
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Supplementary Table 2. Estimates, standard errors and p-values from linear mixed-effects models for the different cognitive domains. Distant PMC, presymptomatic mutation carriers with 
MORE than 5 years to expected symptom onset; Proximity PMC, presymptomatic mutation carriers with LESS than 5 years to expected onset. Values for the following fixed effects are displayed: 
mutated gene (including distant vs proximity PMC). visit (1-3) and the interaction between mutated gene and visit. Other fixed effects in model: years from baseline visit. age. age^2. education. 
sex and baseline score. Random effects: site and individual. The reference is a female, non-carrier at baseline. Ref = estimates, SE and p-value for each genetic group without interaction with 





















Estimate SE p Estimate SE p Estimate SE p Estimate SE p Estimate SE p Estimate SE p Estimate SE p 
 Intercept  0.001 0.077 0.992 -0.130 0.148 0.378 -0.179 0.112 0.110 -0.025 0.103 0.807 0.264 0.155 0.090 -0.279 0.223 0.211 0.171 0.146 0.242 
 Visit2  0.164 0.026 0.000 0.105 0.051 0.040 0.083 0.038 0.029 0.207 0.036 0.000 0.267 0.057 0.000 0.362 0.146 0.013 0.134 0.055 0.015 
 Visit3  0.264 0.045 0.000 0.278 0.087 0.001 0.187 0.066 0.004 0.297 0.061 0.000 0.430 0.098 0.000 0.721 0.264 0.007 0.067 0.094 0.477 
C9 Distant PMC Ref -0.024 0.025 0.348 -0.019 0.049 0.693 -0.020 0.036 0.586 -0.038 0.034 0.264 -0.030 0.053 0.576 -0.074 0.069 0.282 -0.034 0.050 0.496 
  Visit 2 -0.097 0.040 0.017 -0.092 0.080 0.254 -0.024 0.057 0.676 -0.101 0.055 0.066 -0.168 0.087 0.055 -0.037 0.132 0.779 -0.140 0.084 0.096 
  Visit 3 -0.049 0.052 0.353 -0.141 0.104 0.173 0.052 0.074 0.484 0.033 0.071 0.644 0.009 0.112 0.940 -0.132 0.323 0.684 -0.165 0.107 0.123 
 Proximity PMC Ref -0.025 0.042 0.547 -0.089 0.081 0.271 -0.054 0.060 0.367 -0.008 0.056 0.884 -0.015 0.087 0.864 0.008 0.105 0.937 -0.062 0.083 0.455 
  Visit 2 -0.168 0.067 0.013 -0.047 0.134 0.726 -0.021 0.095 0.828 -0.158 0.092 0.086 -0.314 0.146 0.031 0.230 0.182 0.208 -0.450 0.139 0.001 
  Visit 3 -0.281 0.089 0.002 -0.410 0.175 0.020 -0.255 0.126 0.043 -0.147 0.120 0.224 -0.387 0.190 0.042 0.348 0.280 0.215 -0.371 0.180 0.040 
GRN Distant PMC Ref 0.001 0.023 0.978 -0.004 0.045 0.930 -0.001 0.033 0.977 -0.014 0.031 0.644 0.062 0.049 0.206 -0.009 0.066 0.890 0.005 0.046 0.920 
  Visit 2 -0.014 0.035 0.681 0.017 0.070 0.804 0.045 0.049 0.359 -0.049 0.047 0.300 -0.057 0.076 0.456 -0.065 0.109 0.551 0.004 0.073 0.961 
  Visit 3 -0.058 0.042 0.168 -0.060 0.083 0.473 -0.092 0.059 0.121 -0.009 0.057 0.874 -0.102 0.091 0.258 0.107 0.154 0.489 -0.136 0.086 0.117 
 Proximity PMC Ref 0.019 0.039 0.627 0.012 0.077 0.874 0.020 0.056 0.720 0.052 0.053 0.327 -0.019 0.083 0.817 0.045 0.129 0.728 -0.012 0.078 0.878 
  Visit 2 0.007 0.057 0.900 0.200 0.113 0.076 -0.021 0.080 0.794 -0.065 0.077 0.400 -0.121 0.122 0.321 0.340 0.205 0.099 -0.049 0.117 0.676 
  Visit 3 -0.148 0.059 0.013 -0.260 0.118 0.028 -0.285 0.084 0.001 -0.223 0.081 0.006 -0.089 0.128 0.486 0.188 0.259 0.470 0.029 0.122 0.813 
MAPT Distant PMC Ref 0.000 0.036 0.992 -0.008 0.069 0.912 0.018 0.051 0.723 -0.013 0.048 0.787 0.045 0.075 0.548 -0.028 0.102 0.780 -0.013 0.071 0.859 
  Visit 2 0.000 0.052 0.992 -0.053 0.103 0.607 -0.059 0.073 0.418 0.120 0.070 0.087 -0.039 0.112 0.726 -0.034 0.154 0.824 -0.067 0.108 0.537 
  Visit 3 0.138 0.068 0.042 -0.022 0.135 0.873 0.010 0.096 0.915 0.197 0.092 0.033 0.298 0.146 0.042 0.232 0.253 0.360 0.156 0.139 0.263 
 Proximity PMC Ref 0.000 0.052 0.995 -0.045 0.102 0.660 0.003 0.075 0.973 0.027 0.071 0.703 -0.011 0.110 0.918 0.013 0.150 0.931 -0.019 0.104 0.852 
  Visit 2 0.030 0.070 0.672 -0.007 0.141 0.960 0.108 0.099 0.275 0.009 0.096 0.922 0.067 0.154 0.665 0.086 0.217 0.693 0.015 0.150 0.919 
  Visit 3 -0.074 0.093 0.428 -0.282 0.185 0.127 -0.142 0.131 0.281 -0.027 0.126 0.830 -0.167 0.201 0.405 0.210 0.458 0.646 0.400 0.191 0.036 
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Supplementary Table 3. Mixed effects model for global cognitive test scores.  
The reference is a female, non-carrier at baseline. The global practice effect in NC was approximately 0.15 SD per visit. We included baseline scores in our statistical models to eliminate the 
effect of novelty to a task (i.e. stress response at first testing causing interference with performance), and the dilemma of regression to the mean often seen in repeated testing situations. C9, 
chromosome 9 open reading frame 72; GRN, progranulin; MAPT, microtubule associated protein tau; NC, non-carriers; PMC, presymptomatic mutation carriers; AMC, affected mutation 
carriers. 




Intercept 0.000 0.076 0.996 
Visit 2 0.167 0.026 <0.001 
Visit 3 0.270 0.044 <0.001 
PMC-C9 -0.025 0.023 0.279 
PMC-GRN 0.005 0.021 0.825 
PMC-MAPT -0.002 0.030 0.959 
Years from baseline -0.085 0.013 <0.001 
Male -0.016 0.013 0.229 
Age 0.003 0.003 0.416 
Age2 0.000 0.000 0.057 
Education (years) 0.003 0.002 0.151 
Baseline global score 0.888 0.013 <0.001 
Visit 2*PMC-C9 -0.114 0.036 0.002 
Visit 3*PMC-C9 -0.104 0.047 0.027 
Visit 2*PMC-GRN -0.008 0.032 0.790 
Visit 3*PMC-GRN -0.086 0.037 0.021 
Visit 2*PMC-MAPT 0.011 0.043 0.795 
Visit 3*PMC-MAPT 0.064 0.057 0.264 
Random effects Variance   




Site variance of intercept 0.00002   
Residual variance 0.04   
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